BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE 1)
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Sponsor: Bayer
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Bayer
Other Acute Heart Failure trials with similar outcome
Listed as NCT01065077, this PHASE2 trial focuses on Acute Heart Failure and remains terminated or withdrawn. Sponsored by Bayer, it has been updated 8 times since 2010, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bangkok, Thailand , Belgrade, Serbia , Brescia, Italy , Bucharest, Romania , Bunkyo-ku, Japan , Celje, Slovenia , Cleveland, United States , Cluj-Napoca, Romania , Cologne, Germany , Erfurt, Germany and 44 more locations